<DOC>
	<DOCNO>NCT00298298</DOCNO>
	<brief_summary>To determine vaccine make patient 's tumor tissue stimulate immune response patient 's tumor cell . To determine safety vaccine</brief_summary>
	<brief_title>DNP-Modified Autologous Tumor Cell Vaccine Resectable Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>Study Objectives : To study toxicity , safety delayed-type hypersensitivity ( DTH ) responses DNP-modified autologous tumor cell vaccine ( L-Vax ) patient resectable NSCLC : - To determine tolerability toxicity L-Vax - To determine whether L-Vax induces DTH response autologous , DNP-modified NSCLC cell similar magnitude response observe melanoma - Determine whether L-Vax induces DTH response autologous unmodified NSCLC cell - To determine whether DTH responses autologous , unmodified NSCLC cell fix ethanol correlate DTH responses autologous , unmodified NSCLC cell fix Study Population : Patients resectable NSCLC whose therapeutic tumor surgery provide mass , yield adequate tumor , cell vaccine preparation DTH test Study Design : A Phase I/IIa double-blind , three-dose , single center study Investigational Product : L-Vax : DNP-modified autologous NSCLC cell vaccine Dosage Form : Cell suspension Route Administration : Intradermal Dosage Treatment Schedule : Prior vaccine administration , patient test DTH autologous NSCLC cell : DNP-modified , unmodified irradiate , unmodified irradiate fixed ethanol ( sufficient cell available ) Three dos vaccine test : 5 x 105 , 2.5 x 106 , 5 x 106 DNP-modified autologous NSCLC cell . An initial dose DNP-modified autologous NSCLC cells* without Bacillus Calmette Guérin ( BCG ) follow cyclophosphamide ( CY ) weekly dose DNP-modified autologous NSCLC tumor cell mixed BCG 6 week , complete one dose DNP-modified autologous NSCLC tumor cell mixed BCG 6-month booster , adequate number cell available . - count determine prior aliquoting cryopreservation Endpoints : Treatment-emergent related adverse event , serious adverse event , Grade 3 4 laboratory abnormality safety assessments Other Parameters : · DTH skin reaction assess induction immune response DNP-modified unmodified autologous NSCLC tumor cells· Survival· Exploratory analysis vitro study peripheral blood lymphocyte obtain study subject Duration Treatment : Up 9 month Duration Subject Participation Study : Three month patient 's last vaccine Duration Follow-up : Survival information disease status collect via phone visit quarterly basis patient begin 30 day last scheduled visit last patient follow three month his/her last vaccine Number Subjects Required Meet Protocol Objectives : Up 42 evaluable subject Number Study Centers : Three Number Individual Blood Draws : 15 draw nine month Volume Blood Drawn : 13 Draws 30 mL/draw ( total 360 mL ) two draw 50mL heparinized tube</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Histologically document stage IA , IB , IIA , IIB IIIA NSCLC completely resectable require postoperative radiation therapy perioperative chemotherapy Excision tumor harvest tumor mass yield adequate cell vaccine manufacture DTH test Successful preparation lot release vaccine DTH test material contain DNPmodified tumor cell Minimum 3 maximum 8 week since surgery Expected survival least 6 month Karnofsky performance status ³ 80 Signed inform consent Alkaline phosphatase &gt; 2.5 x ULN Total bilirubin &gt; 2.0 mg/dL Creatinine &gt; 2.0 mg/dL Hemoglobin &lt; 10.0 g/dL WBC &lt; 3,000 /mm3 Platelet count &lt; 100,000/mm3 Chemotherapy preoperative postoperative ( except designate protocol ) Radiation therapy lung preoperative postoperative Any major field radiotherapy within 6 month prior participation study Immunotherapy ( interferon , tumor necrosis factor , cytokine [ e.g. , interleukins ] , biological response modifier , monoclonal antibody ) within 4 week prior participation study Prior splenectomy Concurrent use systemic steroid , except period administration adjuvant chemotherapy , per Section 8.6 ( month 47 ) ( Note : Topical steroid therapy [ apply skin ] allow , provide applied limb inject vaccine skin test material . Inhaled aerosol steroid allow . ) Concurrent use immunosuppressive drug , except period administration adjuvant chemotherapy ( month 47 ) Concurrent use antitubercular drug ( isoniazid , rifampin , streptomycin ) Other malignancy within 5 year except curatively treat nonmelanomatous skin cancer curatively treat carcinoma situ uterine cervix , early stage ( stage A B1 ) prostate cancer Concurrent autoimmune disease , e.g. , systemic lupus erythematosus , multiple sclerosis ankylose spondylitis Concurrent medical condition would preclude compliance immunologic response study treatment Concurrent serious infection serious medical condition Receipt investigational medication within 4 week prior participation study Pregnancy lactation ( serum bhuman chorionic gonadotropin [ bHCG ] test must negative fertile woman screen visit ) Active tuberculosis past history tuberculosis PPD positive ( ³ 5 mm 5TU ) Known gentamicin sensitivity Anergic , define inability make DTH least one following : candida , mumps , tetanus trichophyton ( base , except period administration adjuvant chemotherapy ( month 47 ) upon availability ) Vaccine lot release failure</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>lung cancer</keyword>
	<keyword>non-small cell lung cancere</keyword>
	<keyword>vaccine</keyword>
	<keyword>immunotherapy</keyword>
</DOC>